Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas，while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 μg | ¥ 2,960 | 5日内发货 | |
| 50 μg | ¥ 8,900 | 5日内发货 | |
| 500 μg | ¥ 47,100 | 5日内发货 | |
| 1 mg | ¥ 70,600 | 5日内发货 |
| 生物活性 | 1. Loaded Anti-Human Claudin 18.2 mAb-Fc on AHC Biosensor, can bind Human Claudin-18.2-Flag with an affinity constant of 6.76 nM as determined in BLI assay. (Regularly tested)
2. Immobilized Recombinant Human Claudin-18.2-Flag at 5μg/ml (100 μl/well) can bind Anti-Human Claudin 18.2 mAb-Fc. The ED50 of Anti-Human Claudin 18.2 mAb-Fc is 1.54 ng/ml. (Regularly tested) |
| 产品描述 | Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas，while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
| 种属 | Human |
| 表达系统 | HEK293 Cells |
| 标签 | N-Twin strep-Flag |
| 蛋白编号 | P56856-2 |
| 别名 | CLDN18.2,CLDN18,Claudin-18.2,Claudin-18,Claudin 18.2 |
| 氨基酸序列 | Met1-Ala200 |
| 蛋白构建 | Met1-Ala200 |
| 蛋白纯度 | Greater than 70% as determined by reducing SDS-PAGE. Greater than 70% as determined by SEC-HPLC. |
| 分子量 | 18-22 kDa (reducing condition) |
| 内毒素 | < 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
| 缓冲液 | Supplied as a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, 0.06% DDM, 0.012% CHS, 10% Glycerol, pH 7.5. |
| 存储 | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 研究背景 | Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas，while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
嗨！有任何问题？点我咨询
